Abstract: A suction device includes a valve, a piezoelectric pump, and a housing. The valve includes a valve casing and a diaphragm. A first ventilation hole, a second ventilation hole, and a third ventilation hole are formed in the valve casing. The diaphragm is fixed to the valve casing and forms a flow path in the valve casing. The second ventilation hole is opened under atmospheric pressure. The piezoelectric pump has a suction hole and a discharge hole. The discharge hole is in communication with the first ventilation hole. The housing has a cavity. A suction pad is attached to the cavity. The housing forms an enclosed space together with the valve and the piezoelectric pump. The enclosed space is a space that is in communication with the cavity, the suction hole, and the third ventilation hole.

Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A suction device includes a valve, a piezoelectric pump, and a housing. The valve includes a valve casing and a diaphragm. A first ventilation hole, a second ventilation hole, and a third ventilation hole are formed in the valve casing. The diaphragm is fixed to the valve casing and forms a flow path in the valve casing. The second ventilation hole is opened under atmospheric pressure. The piezoelectric pump has a suction hole and a discharge hole. The discharge hole is in communication with the first ventilation hole. The housing has a cavity. A suction pad is attached to the cavity. The housing forms an enclosed space together with the valve and the piezoelectric pump. The enclosed space is a space that is in communication with the cavity, the suction hole, and the third ventilation hole.

Abstract: A fluid control device includes a container and a passive valve. A vacuum source has a suction hole. The container has a first connection hole, a second connection hole, a third connection hole, a storage chamber, and a water-sealing chamber. The passive valve includes a first valve housing, a second valve housing, and a diaphragm. A ventilation hole, a second ventilation hole, and a third ventilation hole are provided in the first valve housing and the second valve housing. The first ventilation hole of the passive valve communicates with the second connection hole of the container. The second ventilation hole of the passive valve communicates with the suction hole of the vacuum source. The third ventilation hole is opened to the atmosphere. The diaphragm is pinched between the first valve housing and the second valve housing and forms a first region and a second region.

Abstract: A database control method includes generating a second database in which recorded contents of a first database are copied, when detecting an update program for updating a first control program configured to control the first database set as a transmission destination of a request for processing transmitted by a terminal apparatus; generating a second control program by updating the first control program using the update program; setting the transmission destination to both the first database and the second database; executing the processing on the first database using the first control program; executing the processing on the second database using the second control program; setting the transmission destination to the second database when a first result of the processing on the first database and a second result of the processing on the second database match; and executing processing on the second database using the second control program when receiving the request.

Abstract: Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.

Abstract: A fluid control device includes a piezoelectric pump, an inhaler, and a valve. The piezoelectric pump has a gas suction hole and a gas discharge hole. The inhaler has a container, an inhalation port, and a connection hole. The valve has a first ventilation hole, a second ventilation hole, a third ventilation hole, a first valve housing, a second valve housing, and a valve body. The first ventilation hole of the valve is connected to the connection hole of the inhaler. The second ventilation hole of the valve is connected to the suction hole of the piezoelectric pump. The third ventilation hole of the valve is opened to the atmosphere. The valve body is held between the first valve housing and the second valve housing, and configures a first region and a second region.

Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.

Abstract: Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.

Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.

Abstract: A fluid control device includes a piezoelectric pump, a suction unit, and a valve. The piezoelectric pump has a suction hole for a gas and a discharge hole for the gas. The suction unit includes a container, a suction port, and a connection hole. The valve includes a first ventilation hole, a second ventilation hole, a third ventilation hole, a first valve housing, a second valve housing, and a diaphragm. The first ventilation hole of the valve is connected to the connection hole of the suction unit. The second ventilation hole of the valve is connected to the suction hole of the piezoelectric pump. The third ventilation hole of the valve is opened under atmospheric pressure. The diaphragm is clamped between the first valve housing and the second valve housing and forms a first region and a second region.

Abstract: A suction device (1) having a suction port (90) exposed outside, a flow passage (91 to 98) communicating with the suction port (90), and a discharge port (99) through which fluid is discharged from the flow passage (91 to 98) includes a diaphragm (83) having one principal surface facing a pump chamber (98) and the other principal surface opposed to the one principal surface, and a piezoelectric element (81) attached to the diaphragm (83) to displace the one principal surface of the diaphragm (83) relative to the pump chamber (98). The one principal surface and the other principal surface of the diaphragm (83) face in a direction different from a direction to which the suction port (90) faces.

Abstract: Disclosed is a switchable transmit and receive phased array antenna (“STRPAA”). As an example, the STRPAA may include a housing, a multilayer printed wiring board (“MLPWB”) within the housing having a top surface and a bottom surface, a plurality of radiating elements located on the top surface of the MLPWB, and a plurality of transmit and receive (“T/R”) modules attached to the bottom surface of the MLPWB. The STRPAA may also include a plurality of vias, wherein each via, of the plurality of vias, passes through the MLPWB and is configured as a signal path between a T/R module, of the plurality of T/R modules, on the bottom surface of the MLPWB and a radiating element, of the plurality of radiating elements, located on the top surface of the MLPWB opposite the T/R module.

Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.

Abstract: A piezoelectric blower includes a housing, top plate, side plate, vibrating plate, piezoelectric element, and cap. The top plate, side plate, and vibrating plate define a blower chamber. The top plate includes a vent hole. The vibrating plate and piezoelectric element constitutes a piezoelectric actuator. The cap includes a wall portion facing the piezoelectric actuator and has a disc-shaped suction port. Here, a central axis of the suction port extending along a thickness direction of the wall portion and a central axis of the piezoelectric element extending along the thickness direction of the wall portion do not coincide with each other. An air channel is provided among the housing, the cap, and a joined structure of the top plate, side plate, and piezoelectric actuator.

Abstract: A light-transmitting apparatus for demultiplexing an input signal completing waveform division multiplexing into wavelength components and transmitting the wavelength components through their respective transmission lines includes a wavelength-count-detecting unit for detecting the number of wavelengths of wavelength components included in the input signal and determining whether the number of wavelengths is normal or abnormal. The light-transmitting apparatus further includes a plurality of identifier-detecting units each associated with one of the wavelength components and used for determining whether or not an identifier set in one of the wavelength components that has the associated wavelength is normal, and a judgment unit for forming a judgment on existence of an error for each of the wavelength components on the basis of a detection result output by the wavelength-count-detecting unit and a detection result output by the identifier-detecting unit associated with the wavelength component.

Abstract: The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

Abstract: The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

Abstract: (Purpose) To perform a dynamic network node management by dividing logically a network, with a physical connection being uniformly configured in a management of nodes over the network. (Solving Means) In response to the inputting of a physical connection database storing a physical connection status related to apparatuses and a server, forming a network, a logical connection condition database storing a condition for a logical connection of the network, and a connection instruction of the logical connection of the network, an apparatus is caused to perform as path calculating means for calculating a path logically connectable from the physical connection database and the physical connection condition database, command generating means for generating a command for modifying, in response to the calculated path, setting to the corresponding apparatus or server, and transmitting means for transmitting the command for modifying the setting.

Abstract: The present invention is a thiobenzimidazole derivative represented by the following formula (1) or a medically acceptable salt thereof wherein said thiobenzimidazole derivative and a medically acceptable salt thereof have a potent activity of inhibiting human chymase. Thus, they are potential preventive and/or therapeutic agents clinically applicable to various diseases in which human chymase is involved.